Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

Nicola Amodio, PhD, Marzia Leotta, MD, Eugenio Morelli, MD, Teresa Calimeri, MD PhD, Anna Maria Gullà, MD, Maria Angelica Stamato, Enrica Romeo, Umberto Foresta, PhDstudent, Antonino Neri, Maria Teresa Di Martino, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2014) 124 (21): 4725.

https://doi.org/10.1182/blood.V124.21.4725.4725

Published: 2014

Journal Articles

MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma

Nicola Amodio, PhD, Marzia Leotta, MD, Anna Maria Gullà, MD, Lavinia Raimondi, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, Teresa Calimeri, MD PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Emanuela Leone, PhD, Antonino Neri, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2014) 124 (21): 2060.

https://doi.org/10.1182/blood.V124.21.2060.2060

Published: 2014

Journal Articles

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Maria Teresa Di Martino, PhD, Annamaria Gullà, MD, Maria Eugenia Gallo Cantafio, Emanuela Altomare, PhD, Nicola Amodio, PhD, Emanuela Leone, PhD, Santo Giovanni Lio, Eugenio Morelli, MD, Daniele Caracciolo, MD, Cirino Botta, MD, Antonino Neri, MD, Niels M Frandsen, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 3166.

https://doi.org/10.1182/blood.V122.21.3166.3166

Published: 2013

Journal Articles

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Cirino Botta, MD, Marco Rossi, MD, Maria Rita Pitari, PhD, Annamaria Gullà, MD, Teresa Del Giudice, MD, Eugenio Morelli, MD, Eleonora Iuliano, MD, Emanuela Altomare, PhD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Pierpaolo Correale, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4489.

https://doi.org/10.1182/blood.V122.21.4489.4489

Published: 2013

Journal Articles

Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells

Nicola Amodio, PhD, Marzia Leotta, MD, Lavinia Biamonte, PhD, Teresa Calimeri, MD, Eugenio Morelli, MD, Umberto Foresta, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Emanuela Leone, PhD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4451.

https://doi.org/10.1182/blood.V122.21.4451.4451

Published: 2013

Journal Articles

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Maria Rita Pitari, PhD, Marco Rossi, MD, Cirino Botta, MD, Eugenio Morelli, MD, Annamaria Gullà, MD, Eleonora Iuliano, MD, Teresa Del Giudice, MD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Fortunato Morabito, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 683.

https://doi.org/10.1182/blood.V122.21.683.683

Published: 2013

Journal Articles

MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile.

Blood (2012) 120 (21): 2941.

https://doi.org/10.1182/blood.V120.21.2941.2941

Published: 2012

Journal Articles

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Marco Rossi, MD, Maria Rita Pitari, PhD student, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Francesco Conforti, MD, Francesco Maria Paolino, PhD student, Cirino Botta, MD, Teresa Del Giudice, MD, Eleonora Iuliano, MD, Manlio Ferrarini, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2012) 120 (21): 3960.

https://doi.org/10.1182/blood.V120.21.3960.3960

Published: 2012

Journal Articles

MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence

Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Nicola Amodio, PhD, Umberto Foresta, PhD, Marta Lionetti, PhD, Maria Rita Pitari, PhD, Maria Eugenia Gallo Cantafio, PhD, Annamaria Gullà, Eugenio Morelli, MD, Marzia Leotta, Vera Tomaino, PhD, Marco Rossi, MD, Massimo Negrini, PhD, Manlio Ferrarini, MD, Antonino Neri, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2011) 118 (21): 2910.

https://doi.org/10.1182/blood.V118.21.2910.2910

Published: 2011

NARROW

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs

MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile.

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only